This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Women's Health, Other  • Diagnosis  • Oncology  • Ovarian Cancer  • Ultrasonography  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2005;294:3075.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Although screening using transvaginal ultrasound (TVU) and testing for a protein biomarker called CA-125 alone or in combination can detect early- and late-stage ovarian cancers, it also results in many false-positives, according to a new study. The findings, from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial sponsored and run by the National Cancer Institute, indicate that using these tests may lead to needless surgeries in some patients (Buys et al. Am J Obstet Gynecol. 2005;193:1630-1639).

An analysis of 28 816 healthy women's initial screening tests found that 1338 women (4.7%) had an abnormal TVU, 402 (1.4%) had an abnormal CA-125 blood test, and 34 women (0.1%) had abnormal results in both screening tests. Among the women with abnormal test results, 570 underwent follow-up surgery that resulted in detection of 29 tumors (20 of which were invasive cancers); 541 women underwent surgery but did not . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Validation of a Self-Administered, Computerized Tool for Collecting and Displaying the Family History of Cancer
Acheson et al.
JCO 2006;24:5395-5402.
ABSTRACT | FULL TEXT